When thousands of oncologists, researchers, and advocates gather at the 2026 ASCO Annual Meeting in Chicago this May, they'll be discussing three pieces of breast cancer research that hint at a shifting understanding of survivorship—not just as the absence of disease, but as a chance to live better.
The American Society of Clinical Oncology's annual conference, running May 29 to June 2, has already begun revealing some of its most promising findings through pre-meeting media briefings. What emerges is a portrait of cancer care expanding beyond chemotherapy and radiation into the everyday tools that help people recover their lives.
The first breakthrough concerns GLP-1 medicines, the class of drugs initially developed for diabetes and weight management. People with stage I, II, or III lung, breast, colorectal, or liver cancer who take a GLP-1 medicine may have a lower risk of their disease progressing to stage IV than those not taking the drugs, according to research presented at the briefing. Mark David Orland, MD, of the Cleveland Clinic, led the study and was careful to frame the finding with appropriate scientific caution. "This is an association, not a cause," he said. "It doesn't apply to all patients and all cancers. But the results are provocative and provide early evidence that future studies are worth pursuing." The comment captures something important: researchers are following promising leads without overpromising cures.
Yoga, meanwhile, has emerged as a surprisingly potent tool for the stubborn side effects that linger long after treatment ends. In the Yoga for Cancer Survivors (YOCAS) study, 410 participants practiced gentle Hatha yoga, with 75 percent having been diagnosed with breast cancer. The structured practice eased mood swings, anxiety, and fatigue—and the improvement rippled into better sleep. Fumiko Chino, MD, an associate professor of breast radiation oncology at MD Anderson Cancer Center, highlighted what makes this finding significant: "This study shows that structured yoga may help relieve some of the most consistently reported and hard-to-treat issues in cancer survivorship, leading to decreased insomnia. It's an important advance because it offers survivors a non-pharmaceutical solution for reducing four different side effects at once."
A third strand of research speaks to the intersection of cancer and obesity. The Breast Cancer Weight Loss (BWEL) study followed people with early-stage breast cancer who were also living with obesity, offering them a structured, phone-based weight loss program. The early results showed that participants moved better and felt better. Jennifer Ligibel, MD, the director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at the Dana-Farber Cancer Institute and lead author of the study, emphasized the broader implication during her media briefing: "We need to stop viewing lifestyle interventions as add-ons and integrate them into care."
These three studies, still in their early stages, point toward a future where breast cancer care treats the whole person—addressing not just the disease itself but sleep, mood, strength, and weight. The 2026 ASCO Annual Meeting will provide a stage for researchers to share more details, and Breastcancer.org will be there documenting every development, ensuring that the hope these findings kindle reaches the people who need it most.